Genomix Molecular Diagnostics Private Limited - Due diligence report

A 360° intelligence report on Genomix Molecular Diagnostics Private Limited: trust score, financial health, credit view, compliance, directo…

2007-01-03 Hyderabad, Telangana Active Unlisted Active Compliant
Share
Connect MCP
GM Genomix Molecular Diagnostics Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Genomix Molecular Diagnostics Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
79/100
Trust Score
Low Risk

Genomix Molecular Diagnostics Private Limited is assessed as Low Risk with a Trust Score of 79/100. Genomix Molecular Diagnostics Private Limited is an active private limited indian non-government company incorporated in 2007, operating in the Life Sciences sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 14 Aug 2026 from the latest processed filings. Genomix Molecular Diagnostics Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
79/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
81/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
55/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.

Charges position: 1 open (29.00 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Department Of Biotechnology1 48.0 cr
Compliance Score: 81/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 1 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
VIJAY KUMAR KANTHAMNENI 01234567 Director 01/04/2018 6 yrs Approved
RATHNAGIRI POLAVARAPU 01234567 Director 01/04/2018 6 yrs Approved
BILHAN KAVIKISHORE POLAVARAPU 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 75
Growth signals & trust indicators
Operating for 19+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
1 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence79/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment62/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 29.00 Lakh already registered.
  • Compliance record supports lending.
Investor view55/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 14 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
29 Nov 2021
Director ceased
BILHAN KAVIKISHORE POLAVARAPU
18 Aug 2021
Director appointed
BILHAN KAVIKISHORE POLAVARAPU (Director)
31 Mar 2020
Share transfer (FY 2020)
4400.00000000 shares to POLAVARAPU OJASVI
Share transfer (FY 2020)
1380.00000000 shares to NUTHALAPATI RAO SESHAGIRI
28 Feb 2019
Director ceased
OJASVI POLAVARAPU
27 Feb 2019
Director ceased
KRISHNAKISHORE KOTA
24 Sep 2012
Securities allotted
2000.00 Equity Shares - 10.00 Lakh raised
07 Sep 2009
Charge created
Department Of Biotechnology - 29.00 Lakh
16 Mar 2009
Securities allotted
4000.00 Equity Shares - 25.00 Lakh raised
03 Jan 2007
Incorporated
Registered with Roc Hyderabad
Director appointed
VIJAY KUMAR KANTHAMNENI (Director)
Director appointed
RATHNAGIRI POLAVARAPU (Director)
10

Key Observations

Auto-generated from the data above
Revenue declined 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Sugen Life Sciences U24230AP2005PTC045939 Tirupathi, Andhra Pradesh, India
Cinetatva Studio Private Limited U72900MH2021PTC355516 Mumbai, Maharashtra, India
Eternal Robotics U73200TG2018PTC129318 Hyderabad, Telangana, India
Chest Research And Training Private Limited U73100PN2020PTC189767 Pune, Maharashtra, India
Mg Biological Private Limited U85190DL2021PTC389496 Delhi, Delhi, India
Eurofins Advinus Discovery Services Private Limited U74999KA2019FTC121801 Bengaluru, Karnataka, India
Parantapa Sciences Private Limited U72900DL2018PTC341470 New Delhi, Delhi, India
Vedicinals India Private Limited U24100PN2017PTC170824 Pune, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Genomix Molecular Diagnostics Private Limited before audits and certifications: compliance score 81/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Genomix Molecular Diagnostics Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Genomix Molecular Diagnostics Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 79/100, distress signals and MSME payment-delay disclosures - know whether Genomix Molecular Diagnostics Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Genomix Molecular Diagnostics Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Genomix Molecular Diagnostics Private Limited an active company?

Genomix Molecular Diagnostics Private Limited has MCA status “Active” with a compliance score of 81/100 (Low Risk).

Is Genomix Molecular Diagnostics Private Limited financially healthy?

Genomix Molecular Diagnostics Private Limited has a Financial Health Score of 55/100 (Moderate) based on its filed financial statements.

Should I do business with Genomix Molecular Diagnostics Private Limited?

Its overall Trust Score is 79/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Genomix Molecular Diagnostics Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Genomix Molecular Diagnostics Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Genomix Molecular Diagnostics Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 81/100 (Low Risk).

Is it risky to lend to Genomix Molecular Diagnostics Private Limited?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.